Targeting human thymidylate synthase: Ensemble-based virtual screening for drug repositioning and the role of water.
Chemotherapy
Drug repositioning
Ensemble docking
Human thymidylate synthase
Virtual screening
Journal
Journal of molecular graphics & modelling
ISSN: 1873-4243
Titre abrégé: J Mol Graph Model
Pays: United States
ID NLM: 9716237
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
07
06
2022
revised:
21
09
2022
accepted:
23
09
2022
pubmed:
19
10
2022
medline:
3
12
2022
entrez:
18
10
2022
Statut:
ppublish
Résumé
A drug repositioning computational approach was carried to search inhibitors for human thymidylate synthase. An ensemble-based virtual screening of FDA-approved drugs showed the drugs Imatinib, Lumacaftor and Naldemedine to be likely candidates for repurposing. The role of water in the drug-receptor interactions was revealed by the application of an extended AutoDock scoring function that included the water forcefield. The binding affinity scores when hydrated ligands were docked were improved in the drugs considered. Further binding free energy calculations based on the Molecular Mechanics Poisson-Boltzmann Surface Area method revealed that Imatinib, Lumacaftor and Naldemedine scored -130.7 ± 28.1, -210.6 ± 29.9 and -238.0 ± 25.4 kJ/mol, respectively, showing good binding affinity for the candidates considered. Overall, the analysis of the molecular dynamics trajectory of the receptor-drug complexes revealed stable structures for Imatinib, Lumacaftor and Naldemedine, for the entire simulation time.
Identifiants
pubmed: 36257147
pii: S1093-3263(22)00227-3
doi: 10.1016/j.jmgm.2022.108348
pii:
doi:
Substances chimiques
lumacaftor
EGP8L81APK
Thymidylate Synthase
EC 2.1.1.45
Water
059QF0KO0R
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108348Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.